Opus Genetics

Opus Genetics Inventory

Inventory of Opus Genetics (IRD) as of Nov 19, 2026.

Inventory

-USD

Last updated:

Inventory of Opus Genetics is 2026 - USD. Inventory of Opus Genetics was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Opus Genetics Stock analysis

What does Opus Genetics do? Ocuphire Pharma, Inc. is a health care company based in Farmington Hills, Michigan, specializing in the research and development of ophthalmic biopharmaceuticals. Listed on the market on 30 November 2004, the firm focuses on therapies for refractive and retinal eye disorders. Its pipeline features Nyxol Eye Drops, a once-daily formulation of phentolamine mesylate aimed at reducing pupil diameter and improving visual acuity for conditions such as presbyopia and night vision disturbances. Additionally, the company develops APX3330, an oral tablet targeting retinal and choroidal diseases, alongside in-licensed second-generation candidates APX2009 and APX2014. The organization employs a small team dedicated to advancing these innovative treatments. Opus Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opus Genetics stock

On Eulerpool you can find the complete historical development of Inventory Opus Genetics since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Opus Genetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Opus Genetics

All Key Metrics — Opus Genetics